UK Drug Discovery sells Cancer Target to German Pharma

18/04/2016 - 2 minutes

Boehringer Ingelheim has bought exclusive rights to an oncology target discovered by Oxford BioTherapeutics and its proteomic database.

oxford_biotherapeutics_boehringer_ingelheim_immunoOxford BioTherapeutics is a Biotech in Milton Park (near Oxford, UK), developing immunotherapies for cancer with antibody-drug conjugates (ADC) – a strategy to combine the specificity of antibodies to a toxic agent that can be delivered to a cancerous cell.

It relies on its proprietary OGAP platform, a cancer proteome database that integrates clinical, experimental and protein expression data. This allows them to discover potential immuno-oncology targets, especially cell surface proteins.

Now, Boehringer Ingelheim has exercised its option to buy a specific drug target from OGAP’s results. Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.

Oxford BioTherapeutics will receive development and regulatory milestone payments, and royalties on any future product sales. But neither the target or the sum received by Oxford BioTherapeutics were disclosed.

This is the result of a collaboration established in 2013 between the 2 companies,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member